OPHTHALMOLOGICAL SCREENING:
CHLOROQUINE RETINOPATHY SCREEN

Chloroquine retinopathy is more common than previously thought.  The incidence is estimated at 7.5% in patients using the drug for more than 5 years.  In patients on the medication for more than 20 years the incidence increases to more than 20%.  Chloroquine retinopathy causes progressive damage to deeper retinal layers in a bull’s eye configuration.  Damage is irreversible and screening is recommended to identify early damage and thus avoid potential progressive damage.  Recent screening guidelines have been amended and adopted by the American Association of Ophthalmologists (AAO) and the Royal College of Ophthalmologists (UK).

Current recommendations are as follows:

  • Patient on Chloroquine for more than 5 years
  • High Risk Cases
    • Long duration of treatment
    • Concomitant Tamoxifen use
    • Concomitant Renal Disease

Baseline Screening:

  • Patients being initiated on Chloroquine should have a baseline ophthalmic screening examination within 6 months of initiation of treatment
  • This should include:
    • Fundus colour photos
    • Macula OCT
    • Wide-Field Autofluorescent Fundus imaging
    • Central Visual Field testing (10-2)

Continued Screening:

  • In high risk cases annually after commencement
  • All other cases annual screening can commence after 5 years

Our practice offers patients the above screening protocol at a reduced price.  Please note that this cash service does not apply for PMB registered patients.

Please use one of the following methods for bookings:

  1. Tel: 041 373 8800
  2. Email: referral@bothadutoit.com
  3. Whatsapp: 066 313 4259